Scrip Asks… What Does 2025 Hold For Biopharma?
Citeline flagship publication Scrip continues in its annual review series, where some of the most influential and important KOLs in the sector review the previous year, and predict outcomes for the next. In Part 5, focused on lifescience and biopharma clinical trial trends, Max Baumann, co-founder and partner of Treehill Partners, concludes the indepth article which is featuring renown industry leaders, with a look at commercial viability.
He says “We expect continued focus on optimizing the development journeys of assets to achieve not only an approval-enabling endpoint but to qualify for commercial success.”
Click here to read the full article on Scrip:
Scrip Asks… What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends